1-(3-Cyclopropyl-5-methylpyridin-2-yl)piperazine hydrochloride → [4-(3-Cyclopropyl-5-methylpyridin-2-yl)piperazin-1-yl][4-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)-2-methanesulfonylphenyl]methanone
Reaction equation
[O:1]=[S:2]1(=[O:20])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[C:9]([S:16]([CH3:19])(=[O:18])=[O:17])[CH:8]=1.Cl.[CH:22]1([C:25]2[C:26]([N:32]3[CH2:37][CH2:36][NH:35][CH2:34][CH2:33]3)=[N:27][CH:28]=[C:29]([CH3:31])[CH:30]=2)[CH2:24][CH2:23]1>>[CH:22]1([C:25]2[C:26]([N:32]3[CH2:37][CH2:36][N:35]([C:11]([C:10]4[CH:14]=[CH:15][C:7]([N:3]5[CH2:4][CH2:5][CH2:6][S:2]5(=[O:1])=[O:20])=[CH:8][C:9]=4[S:16]([CH3:19])(=[O:18])=[O:17])=[O:13])[CH2:34][CH2:33]3)=[N:27][CH:28]=[C:29]([CH3:31])[CH:30]=2)[CH2:23][CH2:24]1Participants
3
Reactant 2
Product 1
Procedure
Using 4-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methanesulfonylbenzoic acid (319 mg) described in Preparation Example 22 and 1-(3-cyclopropyl-5-methylpyridin-2-yl)piperazine hydrochloride (254 mg) described in Preparation Example 85 and by the reaction and treatment in the same manner as in Example 86, the title compound (360 mg) was obtained.
Workup
- customdescribed in Preparation Example 85 and by the reaction and treatment in the same manner as in Example 86
Sources & evidence
- ORD record
- ord-31d51661fd3b4598b9b500da41009861
- Source dataset
- uspto-grants-2014_08
- Patent number
- US08816079B2
Reaction notes
Loading…